Sun Pharmaceutical Q2 FY27: PAT ₹28,948 Cr & Rev ₹1.52 L Cr

Metric	Value
Revenue	₹1.52 L Cr
Net Profit (PAT)	₹28,948 Cr

📢 Key Event
Sun Pharma Q1 FY27 earnings call highlights revenue growth and strategic updates

🔄 What Changed
Adjusted net profit rose to INR30,894 million; U.S. generic sales declined 9.7% YoY; emerging market growth slowed to 4%

🔮 What's Next
High single-digit full-year revenue growth maintained

💡 Investor Takeaway
Growth is driven by innovation and domestic volume, but U.S. generic pressure and emerging market headwinds pose near-term challenges

Sun Pharmaceutical reported Q1 FY27 revenue of INR1,51,836 million, up 10.1% YoY, with net profit at INR28,948 million and adjusted net profit of INR30,894 million. EBITDA stood at INR44,177 million, reflecting strong performance in innovative medicines (up 12.8% to USD351 million) and India (16% growth, 8.5% market share). U.S. generic sales declined 9.7% due to Lenalidomide loss, though new launches support future growth. Management highlighted pipeline progress, including semaglutide approvals in South Africa and Brazil, and sustained R&D investment at 5.4% of sales. Gross margin expansion is expected from product mix shifts, with full-year revenue growth guided at high single digits despite emerging market headwinds and forex volatility.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Limited (SUNPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹4,50,643.09 Cr P/E: 41.3 ROE: 15.1% ROCE: 20.3%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

💡 Ask AI about this filing

"How will U.S. generic erosion impact margins long-term?" "What is the timeline for semaglutide launches in Brazil?" "When will MM-II out-licensing generate meaningful returns?"

Ask AI Free →

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

🔥 Also filed on 6 August 2026

CHAMBLFERT Chambal Fertilizers & Chemicals Limited Financial Results VSTL Vibhor Steel Tubes Limited Financial Results VISAKAIND Visaka Industries Limited Corporate Action VISAKAIND Visaka Industries Limited Corporate Action SUMEETINDS Sumeet Industries Limited Financial Results VAML Vedanta Aluminium Metal Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.